These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20576503)

  • 1. A new ligand for targeted drug delivery to tumor stromal cells.
    Park K
    J Control Release; 2010 Jul; 145(2):75. PubMed ID: 20576503
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier.
    Prakash J; de Jong E; Post E; Gouw AS; Beljaars L; Poelstra K
    J Control Release; 2010 Jul; 145(2):91-101. PubMed ID: 20362019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumor stromal cells through a PDGF-beta receptor binding carrier.
    Prakash J; de Jong E; Post E; Mohammad AK; Beljaars L; Poelstra K
    J Control Release; 2010 Nov; 148(1):e116. PubMed ID: 21529587
    [No Abstract]   [Full Text] [Related]  

  • 4. Doxorubicin in sterically stabilized liposomes.
    Lasic DD
    Nature; 1996 Apr; 380(6574):561-2. PubMed ID: 8606781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions.
    Nakamura T; Matsumoto K; Kiritoshi A; Tano Y; Nakamura T
    Cancer Res; 1997 Aug; 57(15):3305-13. PubMed ID: 9242465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth.
    Bansal R; Tomar T; Ostman A; Poelstra K; Prakash J
    Mol Cancer Ther; 2012 Nov; 11(11):2419-28. PubMed ID: 22933708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo.
    Song S; Liu D; Peng J; Sun Y; Li Z; Gu JR; Xu Y
    Int J Pharm; 2008 Nov; 363(1-2):155-61. PubMed ID: 18692120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy: a means to enhanced drug delivery to tumors.
    Snyder JW; Greco WR; Bellnier DA; Vaughan L; Henderson BW
    Cancer Res; 2003 Dec; 63(23):8126-31. PubMed ID: 14678965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice.
    Mizuno Y; Naoi T; Nishikawa M; Rattanakiat S; Hamaguchi N; Hashida M; Takakura Y
    J Control Release; 2010 Jan; 141(2):252-9. PubMed ID: 19778560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro anti-cancer activities and enhanced cellular uptakes of EGF fragment decorated doxorubicin nano-aggregates.
    Park S; Yoo HS
    Int J Pharm; 2010 Jan; 383(1-2):178-85. PubMed ID: 19732814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
    Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R
    J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin.
    Ren Y; Wong SM; Lim LY
    Bioconjug Chem; 2007; 18(3):836-43. PubMed ID: 17407258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H; Tzemach D; Mak L; Gabizon A
    J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
    Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
    J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted magnetic liposomes loaded with doxorubicin.
    Pradhan P; Banerjee R; Bahadur D; Koch C; Mykhaylyk O; Plank C
    Methods Mol Biol; 2010; 605():279-93. PubMed ID: 20072888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Retarded pharmaceuticals' assuming a clinical role.
    Muggia FM
    Onkologie; 2004 Oct; 27(5):437-8. PubMed ID: 15585972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.